ERK5 Antibody (YA4227)

ERK5 (MAPK7), also known as big mitogen-activated protein kinase 1 (BMK1), is a distinct member of the mitogen-activated protein kinase (MAPK) family that integrates extracellular signals to regulate proliferation, differentiation, survival, transcriptional control, and tissue homeostasis^[1][2]. Mechanistically, ERK5 is uniquely activated by MEK5 and contains an N-terminal kinase domain together with a large C-terminal transcriptional activation domain, enabling coordinated regulation of kinase-dependent and transcriptional responses^[1][3]. Through the MEK5/ERK5 signaling axis, ERK5 participates in endothelial adaptation to laminar shear stress, promotes cell survival, and contributes to cardiovascular homeostasis by regulating protective transcriptional programs such as KLF2 expression^[2]. In disease settings, aberrant ERK5 signaling has been associated with cancer progression, including enhanced migration, invasion, epithelial-mesenchymal transition, and metastatic behavior in multiple tumor models^[1][4]. Compared with related ERK isoforms, ERK5 is distinguished by its unusually large C-terminal region containing transcriptional activation and nuclear localization elements, which confer functions beyond classical MAPK catalytic signaling^[1][3]. Alternative ERK5 isoforms further diversify its biological activity, and a short isoform lacking the C-terminal transcriptional domain and nuclear localization signal has been linked to altered nucleocytoplasmic trafficking, increased cell migration, epithelial-mesenchymal transition, and poor outcomes in breast cancer models^[5]. For experimental applications, selective ERK5 inhibitors and chemical probes have been developed to investigate ERK5-dependent signaling networks and disease mechanisms, supporting its continued use as a pharmacological target in cancer and vascular biology research^[3].